Sandoz continues European revamp
2021; American Chemical Society; Volume: 99; Issue: 19 Linguagem: Inglês
10.1021/cen-09919-buscon13
ISSN2474-7408
Autores Tópico(s)Pharmaceutical Economics and Policy
ResumoThe generic-drug maker Sandoz will spend $60 million on new production technology and increased capacity for making sterile penicillin active pharmaceutical ingredients (APIs) and sterile API mixtures in Palafolls, Spain. In a related action, Sandoz will close its site in Les Franqueses del Vallès, Spain, which produces oral APIs, in 2024. The moves complement the firm's previously announced plan to spend $120 million to expand and modernize its amoxicillin plant in Kundl, Austria, which it calls the last of its kind in Europe.
Referência(s)